诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

休市中 12-20 15:59:59 EST

97.08

+0.31

+0.32%

盘后97.11

+0.000.00%

19:35 EST

最高97.58	最低96.06	成交量154.77万
今开96.15	昨收96.77	日振幅1.57%
总市值1,941亿	流通市值1,852亿	总股本19.99亿
成交额1.50亿	换手率0.08%	流通股本19.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":97.08,"timestamp":1734728399988,"preClose":96.77,"halted":0,"volume":1547661,"hourTrading":{"tag":"盘后","latestPrice":97.11,"preClose":97.11,"latestTime":"19:35 EST","volume":46153,"amount":4481921.19,"timestamp":1734741308116},"delay":0,"floatShares":1907926384,"shares":1999270033,"eps":8.578162,"marketStatus":"休市中","marketStatusCode":7,"change":0.31,"latestTime":"12-20 15:59:59 EST","open":96.15,"high":97.58,"low":96.062,"amount":150162566.87889,"amplitude":0.015687,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.578162,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":1,"adjPreClose":96.77,"adrRate":1,"dividendRate":0.040368,"preHourTrading":{"tag":"盘前","latestPrice":96,"preClose":96.77,"latestTime":"09:13 EST","volume":5210,"amount":501294.56086,"timestamp":1734704034413},"postHourTrading":{"tag":"盘后","latestPrice":97.11,"preClose":97.11,"latestTime":"19:35 EST","volume":46153,"amount":4481921.19,"timestamp":1734741308116},"volumeRatio":1.2823048799151127,"impliedVol":0.2294,"impliedVolPercentile":0.7222},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"2492275186","title":"Bioage Labs宣布与诺华制药(NVS.N)开展多年合作，以发现治疗与年龄相关疾病和病症的新靶点。","url":"https://stock-news.laohu8.com/highlight/detail?id=2492275186","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492275186?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:04","pubTimestamp":1734530683,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4578","IE00B4R5TH58.HKD","BK4007","01477","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0211331839.USD","BK4585","BK1191","BK4532","BK1574","NVS","IE0002141913.USD","BK4588","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2491261696","title":"北方华创：参与设立北京集成电路装备产业投资并购二期基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2491261696","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491261696?lang=zh_cn&edition=full","pubTime":"2024-12-16 21:42","pubTimestamp":1734356522,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE00B2B36J28.USD","SGXZ81163826.USD","LU1064130708.USD","IE0002141913.USD","BK4578","BK0239","BK0028","BK4532","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","SGXZ49509284.SGD","SG9999001093.SGD","BK4588","IE00BJT1NW94.SGD","159582","LU1064131003.USD","LU1997244956.HKD","LU2328871848.SGD","BK0276","BK4585","000931","601066","IE0009355771.USD","NVS","BK0075","LU2495084118.USD","BK0188","BK0125","LU1969619763.USD","SG9999003461.SGD","159982","BK4007","LU2148510915.USD","LU1997245177.USD","IE00BFTCPJ56.SGD","BK0251","002371","LU0211331839.USD","LU1997245094.SGD","BK0178","LU1328615791.USD","159546"],"gpt_icon":0},{"id":"2491574206","title":"8家创新药公司获融资！免疫疾病疗法新锐获强生、诺华支持 | 一周融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2491574206","media":"创鉴汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491574206?lang=zh_cn&edition=full","pubTime":"2024-12-16 17:11","pubTimestamp":1734340270,"startTime":"0","endTime":"0","summary":"生物医药领域共8家公司获融资，涉及药物类型包括创新小分子、放射性疗法、抗体药物等。安济盛期待这两种双特异性药物将有助于促进患者更强健且更有序的骨骼发育。目前，安济盛正在招募绝经后女性骨质疏松症患者参与AGA2118临床2期试验，AGA2115目前处于临床1期试验阶段。筹集的资金将用于支持临床试验的准备工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216173457ab7bf68f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216173457ab7bf68f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BGHQF631.EUR","IE00BSNM7G36.USD","BK4578","LU0114720955.EUR","LU0234572021.USD","IE0002270589.USD","LU1674673691.USD","LU1718418525.SGD","LU1778281490.HKD","LU1674673428.USD","LU0792757196.USD","SG9999001440.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","BK4504","LU1280957306.USD","LU0289739699.SGD","BK4592","LU1066051225.USD","IE00B42XCP33.USD","BK4585","LU2602419157.SGD","BK4559","LU1162221912.USD","LU0466842654.USD","LU2347655156.SGD","LU0795875169.SGD","LU1894683264.USD","JNJ","LU1244550494.USD","LU0058720904.USD","LU1732799900.SGD","NVS","LU0345769631.USD","LU1244550221.USD","LU1261432733.SGD","LU0912757837.SGD","LU0640476718.USD","LU1066051811.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4581","LU0882574055.USD","LU2468319806.SGD","BK4532","BK4534","LU0795875086.SGD","BK4588","LU0098860793.USD","BK4007"],"gpt_icon":0},{"id":"2490868675","title":"诺华制药跌0.42% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490868675?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:31","pubTimestamp":1733927508,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时31分，诺华制药股票出现异动，股价急速下挫0.42%。截至发稿，该股报99.71美元/股，成交量3.8035万股，换手率0.00%，振幅0.13%。机构评级方面，在所有28家参与评级的机构中，21%的券商给予买入建议，68%的券商给予持有建议，11%的券商给予卖出建议。诺华制药股票所在的制药行业中，整体跌幅为0.40%。诺华制药公司简介：诺华开发和生产创新型药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223149ab6fc9fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223149ab6fc9fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","IE0009355771.USD","IE00B2B36J28.USD","IE0002141913.USD","BK4578","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","NVS","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4585","BK4532","BK4007"],"gpt_icon":0},{"id":"2490864360","title":"西门子医疗完成对诺华分子成像业务的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2490864360","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490864360?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:28","pubTimestamp":1733887680,"startTime":"0","endTime":"0","summary":"西门子医疗收购诺华公司分子成像业务 这项交易扩展了西门子医疗在欧洲的PET放射性药物生产网络 将更好地为癌症、心脏和神经疾病患者提供支持  芝加哥2024年12月11日 /美通社/ -- 近日，西门子医疗完成了对诺华公司Advanced Accelerator Applications分子成像业务的收购。此次收购强化了西门子医疗的PETNET Solutions网络。西门子医疗致力于提升优质医疗资源可及性，同时攻克威胁人类健康的致命疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4577184_ZH77184_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE0002141913.USD","BK4588","SIEGY","BK4082","BK4007","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE00B4R5TH58.HKD","BK4532","NVS","IE00BJT1NW94.SGD","SMMNY","BK4578","BK4585","BK4206","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2489144246","title":"更新版 1-美国上诉法院称，诺华不能阻止最畅销心脏病药物的仿制药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2489144246","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489144246?lang=zh_cn&edition=full","pubTime":"2024-12-05 04:44","pubTimestamp":1733345055,"startTime":"0","endTime":"0","summary":"美国联邦巡回上诉法院维持了特拉华州联邦法官8月份的判决，该判决认定诺华未能证明其有可能赢得针对MSN的专利诉讼，这为MSN推出美国首款Entresto仿制药扫清了障碍。MSN 的 Entresto 版本已于今年 7 月获得美国食品和药物管理局的批准。诺华在获得 FDA 批准后申请了一项初步禁令，以阻止 MSN 在该案期间推出其仿制药，该案将于下周一开庭审理。在诺华公司向联邦巡回法院提出上诉期间，法官暂停了MSN推出其拟议的仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"更新版 1-美国上诉法院称，诺华不能阻止最畅销心脏病药物的仿制药上市","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B2B36J28.USD","BK4585","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4578","IE00BJT1NW94.SGD","IE0002141913.USD","NVS","BK4007","BK4532","IE0009355771.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2488067958","title":"PTC Therapeutics(PTCT.US)与诺华制药(NVS.US)签署亨廷顿病药物许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488067958","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488067958?lang=zh_cn&edition=full","pubTime":"2024-12-02 21:23","pubTimestamp":1733145808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物制药公司PTC Therapeutics的股价周一盘前上涨21%，此前该公司与诺华制药签署了PTC518亨廷顿病项目的独家全球许可和合作协议。PTC518目前正在进行2期PIVOT-HD试验，并显示出良好的安全性和耐受性。该协议预计将于2025年第一季度完成。根据协议，PTC Therapeutics 将获得10亿美元的预付款，高达19亿美元的开发、监管和销售里程碑，在美国的利润分成为40%，并在美国以外的地区获得两位数的销售分层版税。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2506952337.HKD","LU0889565916.HKD","BK4532","BK4139","BK4554","BK4023","BK1574","LU2362540622.SGD","PTCT","IE00B2B36J28.USD","IE0002141913.USD","BK4588","LU1721428347.USD","BK1191","BK4578","01477","PTC","LU1951200564.SGD","LU1923623000.USD","LU2477742899.HKD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4585","LU2506952410.USD","IE00BJJMRZ35.SGD","LENZ","LU1951198990.SGD","LU2362541273.HKD","NVS","LU2362541513.USD","BK4576","LU0109394709.USD","LU0211331839.USD","IE0009355771.USD","BK4007","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2488967568","title":"BUZZ-PTC Therapeutics 因与诺华签署高达 29 亿美元的许可协议而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2488967568","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488967568?lang=zh_cn&edition=full","pubTime":"2024-12-02 20:40","pubTimestamp":1733143219,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    12月2日 - ** PTC Therapeutics   股价盘前上涨20.5%至52.89美元 ** 该公司称制药商诺华  将为PTCT的候选药物PTC518支付10亿美元预付款和最多19亿美元的里程碑付款，该药物正在开发中，用于治疗亨廷顿氏症** NOVN 将负责该药物的开发、生产和商业化。** PTCT 和 NOVN 将分别按 40/60 的比例分享该药物在美国的利润和损失** 截至上一交易日收盘，股价累计上涨 59.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951200564.SGD","BK4554","LU1923623000.USD","BK4023","BK4139","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4578","LENZ","LU2362541513.USD","LU0109394709.USD","LU2506952410.USD","PTCT","LU0211331839.USD","NVS","LU1951198990.SGD","IE0002141913.USD","PTC","LU2362541273.HKD","BK4576","LU2506952337.HKD","IE00B4R5TH58.HKD","LU2362540622.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4588","LU2477742899.HKD","IE00BJT1NW94.SGD","LU1721428347.USD","BK4007","BK4532","IE00B2B36J28.USD","BK4585","IE0009355771.USD"],"gpt_icon":0},{"id":"2488967535","title":"更新版 1-更正-PTC Therapeutics 与诺华签订价值 29 亿美元的许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488967535","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488967535?lang=zh_cn&edition=full","pubTime":"2024-12-02 20:35","pubTimestamp":1733142942,"startTime":"0","endTime":"0","summary":"     路透社12月2日 - PTC Therapeutics   已与诺华公司  签署了一项高达29亿美元的许可协议，用于该美国公司治疗一种罕见神经系统疾病的实验性药物，这使其股价在周一的盘前交易中上涨了20%。诺华公司将为 PTC 的候选药物 PTC518 提供 10 亿美元的预付款和高达 19 亿美元的里程碑付款，PTC518 正在开发中，用于治疗亨廷顿氏症。PTC 和诺华将分别按 40/60 的比例分享该药在美国的利润和损失。两家公司预计交易将于 2025 年第一季度完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE0009355771.USD","IE00B4R5TH58.HKD","LU1951200564.SGD","IE0002141913.USD","NVS","BK4585","LU2506952410.USD","IE00BJT1NW94.SGD","BK4578","BK4554","LENZ","LU2362540622.SGD","LU0320765992.SGD","PTC","LU2362541513.USD","LU0109394709.USD","PTCT","LU0889565916.HKD","LU1951198990.SGD","LU2362541273.HKD","LU2477742899.HKD","LU2506952337.HKD","BK4023","LU0211331839.USD","LU1721428347.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4139","BK4007","IE00BFTCPJ56.SGD","BK4576","BK4588","LU1923623000.USD"],"gpt_icon":0},{"id":"2486848893","title":"诺华(NVS.US)重磅小分子药物再获欧盟委员会批准 有望变革早期乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2486848893","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486848893?lang=zh_cn&edition=full","pubTime":"2024-11-28 07:43","pubTimestamp":1732751026,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华公司今天宣布，欧盟委员会已批准CDK4/6抑制剂Kisqali联合芳香酶抑制剂，作为辅助疗法，治疗激素受体阳性、人表皮生长因子受体2阴性的高复发风险早期乳腺癌患者。这一批准基于关键性3期临床试验NATALEE的结果，该试验涵盖了广泛的患者群体，包括HR+/HER2-的II期和III期早期乳腺癌患者，其中也包括无淋巴结转移的患者。诺华将继续对NATALEE患者进行长期结果的评估，包括总生存期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4578","IE0009355771.USD","BK4532","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0211331839.USD","BK4007","IE00B2B36J28.USD","NVS","BK4588","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2486094525","title":"诺华(NVS.US)的盐酸阿曲生坦片国内报上市 适应症为IgA肾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2486094525","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486094525?lang=zh_cn&edition=full","pubTime":"2024-11-26 09:32","pubTimestamp":1732584737,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11 月 26 日，CDE 官网显示，诺华的盐酸阿曲生坦片在国内报上市，适应症为用于降低有疾病进展风险的原发性免疫球蛋白 A 肾病成人患者的蛋白尿，此前已纳入优先审评。阿曲生坦有可能添加到目前的支持疗法中，以减少持续性蛋白尿并保护广大患者群体的肾功能。临床前模型也表明阿曲生坦可以减少 IgAN 中的炎症和纤维化。研究还显示，阿曲生坦具有良好的安全性，与前期报道的数据一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE00B2B36J28.USD","BK4585","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4578","IE00BJT1NW94.SGD","IE0002141913.USD","NVS","BK4007","BK4532","IE0009355771.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2485478366","title":"诺华上调未来几年销售额年度增长预期至6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485478366","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485478366?lang=zh_cn&edition=full","pubTime":"2024-11-22 07:31","pubTimestamp":1732231895,"startTime":"0","endTime":"0","summary":"瑞士制药巨头诺华集团周四上调了其中期销售预期，目前预计到2028年的年增长率为6%，原因是已上市药物的强劲势头和即将上市药物的前景。该公司此前的中期目标是2023年至2028年经汇率调整后的销售额增长至少5%。然而，该公司表示，鉴于其在2024年的强劲表现，仍预计2024-2029年期间每年的销售额将增长5%。诺华将于周四举行一场投资者活动，该公司重申，到2027年，其核心利润率目标至少为40%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/22073145553881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["NVS","BK4585","BK4532","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","IE0009355771.USD","LU0211331839.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4588","BK4578","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2485963418","title":"医药早参丨基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2485963418","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485963418?lang=zh_cn&edition=full","pubTime":"2024-11-21 22:50","pubTimestamp":1732200618,"startTime":"0","endTime":"0","summary":"丨 2024年11月22日 星期五 丨NO.1基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期11月21日，基于对新的癌症和免疫疾病药物以及神经和心血管疾病治疗药物的乐观预期，诺华制药上调了中期销售预期。公司贝伐珠单抗注射液获得国家药监局批准上市，视同通过生物类似药相似性评价。该药品获批生产和销售将对公司未来经营业绩产生积极影响。截至目前，HRS-6208胶囊相关项目累计已投入研发费用约为2378万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121225052a24b7e72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121225052a24b7e72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4578","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4585","BK4532","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0002141913.USD","NVS","BK4588","LU0211331839.USD","IE0009355771.USD","BK4007","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"1183551855","title":"基于癌症和炎症药物乐观前景，诺华上调中期销售预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1183551855","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183551855?lang=zh_cn&edition=full","pubTime":"2024-11-21 17:31","pubTimestamp":1732181469,"startTime":"0","endTime":"0","summary":"公司营收将以每年6%的速度增长。","market":"us","thumbnail":"https://static.tigerbbs.com/7766c80d5c26c9599970478e92d8da00","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/7766c80d5c26c9599970478e92d8da00"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1214014.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVS"],"gpt_icon":1},{"id":"2484678465","title":"Ratio与诺华(NVS)签订许可与合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2484678465","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484678465?lang=zh_cn&edition=full","pubTime":"2024-11-18 21:54","pubTimestamp":1731938073,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药物研发和制造公司Ratio Therapeutics于11月18日宣布，与诺华制药(NVS)的子公司Novartis Pharma签署了一项全球独家许可与合作协议，该合作利用Ratio的放射性配体疗法发现和开发专长及其技术平台，开发治疗癌症的生长抑素受体2（SSTR2）放射性治疗候选药物。根据协议条款，Ratio将获得高达7.45亿美元的预付款和潜在的里程碑付款，并有资格获得分级特许权使用费。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282120","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","BK4585","IE00B2B36J28.USD","BK4578","IE0009355771.USD","BK4007","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4532","IE0002141913.USD","IE00B4R5TH58.HKD","NVS","IE00BFTCPJ56.SGD","BK4588"],"gpt_icon":0},{"id":"2483151011","title":"诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2483151011","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483151011?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:54","pubTimestamp":1731466452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11 月 13 日，诺华的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理。该药是 FDA 批准的首个针对去势抵抗性前列腺癌患者的靶向放射性配体疗法，本次是在国内首次报上市。以放射配体疗法为代表的核药是诺华重金布局的领域。除了 Pluvicto，诺华还有一款核药 Lutathera 也已获批上市，用于生长抑素受体阳性胃肠胰神经内分泌肿瘤成人患者， 后又获批用于12 岁及以上儿童患者。Lutathera 2023 年销售额达 6.05 亿美元，2024 前三个季度销售额为 5.34 亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4578","BK4585","BK4588","CDE","BK4017","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","BK4532","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","IE00B4R5TH58.HKD","NVS"],"gpt_icon":0},{"id":"2482704449","title":"金十数据整理：每日美股市场要闻速递（11月12日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2482704449","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482704449?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:31","pubTimestamp":1731418319,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["CDE","BK4578","BK4007","TIGR","BK4017","IE00B19Z3B42.SGD","IE00BGHQF631.EUR","LU1066053197.SGD","RDSA.UK","LU1162221912.USD","BK4532","NVS","BK4513","AZN","BK4127","LU0640476718.USD","IE0002141913.USD","BK4588","BK4533","NQGM","IE00B3PB1722.GBP","LU0792757196.USD","BK4563","BA","BK4515","LU2462157665.USD","RDS.A","IE00BVYPNW00.USD","DELL","SHEL","HUYA","LU0889566641.SGD","LU0345769128.USD","RDS.B","BK4526","LU0109394709.USD","GPRO","AVNW","LU0345769631.USD","JNJ","IE0009355771.USD","161631","01477","IE00BJT1NW94.SGD","BK4078","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BK4592","LU0320765992.SGD"],"gpt_icon":0},{"id":"2482703103","title":"BUZZ-薛定谔与诺华公司的研究合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703103","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482703103?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:17","pubTimestamp":1731413820,"startTime":"0","endTime":"0","summary":"    11月12日 - ** 制药软件公司Schrodinger   股价盘前上涨6.5%至20.81美元** 该公司宣布与诺华  达成研究合作与许可协议，\"将多个候选开发项目纳入诺华的产品组合，以便进一步开发\"。** 还宣布扩大与诺华公司为期三年的软件协议** 根据协议条款，co 将获得 1.5 亿美元的预付款，并有资格获得高达 8.92 亿美元的里程碑付款。** 此外，Co 还有资格获得高达 13.8 亿美元的商业里程碑款项，以及诺华公司商业化的每种产品净销售额的中个位数至低两位数的分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","NVS","SDGR","BK4585","BK4532","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","IE0009355771.USD","LU0211331839.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4588","BK4578","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2482974614","title":"治疗IgA肾病！诺华(NVS.US)阿曲生坦拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2482974614","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482974614?lang=zh_cn&edition=full","pubTime":"2024-11-12 13:45","pubTimestamp":1731390335,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11 月 12 日，CDE官网显示，诺华的盐酸阿曲生坦片拟纳入优先审评，适应症为用于降低有疾病进展风险的原发性免疫球蛋白A肾病成人患者的蛋白尿。阿曲生坦有可能添加到目前的支持疗法中，以减少持续性蛋白尿并保护广大患者群体的肾功能。临床前模型也表明阿曲生坦可以减少IgAN中的炎症和纤维化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","BK4007","BK4585","IE00BJT1NW94.SGD","IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4578","NVS","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4588","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2481905593","title":"诺华的两步大棋","url":"https://stock-news.laohu8.com/highlight/detail?id=2481905593","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481905593?lang=zh_cn&edition=full","pubTime":"2024-11-07 19:47","pubTimestamp":1730980071,"startTime":"0","endTime":"0","summary":"诺华，在一众大药企中算得上是一个独特的存在。诺华却不“跟风”，而是加速瘦身，从不具优势的领域撤退，进一步加大新兴技术平台布局，包括靶向蛋白质降解技术、细胞疗法、基因疗法、放射性配体疗法以及RNA疗法。在今年的进博会上，诺华重点展示了放射配体疗法、长效降脂药以及肾病管线组合，并设立专区，展示其深耕国内县域市场的决心。本届进博会上，诺华的放射配体疗法是“展品推动重大投资及落地”的典型例子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/244059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4007","IE00B4R5TH58.HKD","IE0002141913.USD","BK4532","IE0009355771.USD","NVS","LU0211331839.USD","BK4585","IE00B2B36J28.USD","BK4578","IE00BJT1NW94.SGD","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":-0.013},{"period":"1month","weight":-0.0583},{"period":"3month","weight":-0.1627},{"period":"6month","weight":-0.0774},{"period":"1year","weight":-0.0104},{"period":"ytd","weight":-0.0385}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日在瑞士成立。该公司提供满足全球患者和社会不断变化的需求的医疗保健解决方案。他们广泛的产品组合包括创新药物和肿瘤药物，仿制药和生物仿制药以及眼科护理设备。他们的使命是发现改善和延伸人们生活的新方法。他们的愿景是成为改变医学实践的值得信赖的领导者。他们的战略是利用科学的创新在不断增长的医疗领域提供更好的患者结果。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.014981},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.012188},{"month":3,"riseRate":0.5,"avgChangeRate":0.000575},{"month":4,"riseRate":0.708333,"avgChangeRate":0.018746},{"month":5,"riseRate":0.666667,"avgChangeRate":0.008804},{"month":6,"riseRate":0.56,"avgChangeRate":0.010664},{"month":7,"riseRate":0.72,"avgChangeRate":0.014267},{"month":8,"riseRate":0.4,"avgChangeRate":-0.003307},{"month":9,"riseRate":0.68,"avgChangeRate":0.009526},{"month":10,"riseRate":0.44,"avgChangeRate":-0.01226},{"month":11,"riseRate":0.6,"avgChangeRate":0.014931},{"month":12,"riseRate":0.68,"avgChangeRate":0.019093}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}